Welcome to our dedicated page for Transcode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on Transcode Therapeutics stock.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) generates a steady flow of news as a clinical-stage oncology company advancing RNA-targeted therapeutics for cancer. This news page aggregates press releases and third-party coverage related to TransCode’s development programs, corporate actions, and scientific collaborations, giving readers a centralized view of how the company’s RNA oncology strategy is progressing.
Much of the company’s news focuses on its lead candidate, TTX-MC138, an RNA-based therapeutic designed to inhibit microRNA-10b (miR-10b), which TransCode identifies as a key factor in metastatic cancer. Updates include milestones from its Phase 0 and Phase 1a clinical trials in metastatic solid tumors, reports on safety and pharmacodynamic data, and announcements about advancing TTX-MC138 into Phase 2a studies across selected metastatic indications and minimal residual disease settings.
Readers can also follow news about preclinical research using the TTX platform, such as studies in glioblastoma models demonstrating delivery of TTX-MC138 to brain tumors, target engagement, and extended survival in murine models. These items highlight how TransCode’s nanoparticle platform is being evaluated for systemic delivery of RNA therapeutics to challenging tumor sites.
Beyond clinical and preclinical data, TransCode’s news includes corporate and strategic developments, such as the acquisition of Polynoma and the addition of seviprotimut-L, a polyvalent shed antigen vaccine for stage IIB and IIC melanoma, to its pipeline. Filings and releases also cover financing transactions with affiliates of CK Life Sciences, reverse stock split decisions related to Nasdaq listing requirements, and governance updates including board and executive appointments.
For investors, researchers, and clinicians, following RNAZ news offers insight into TransCode’s progress in metastatic disease, its expanding immuno-oncology and RNA pipeline, and the regulatory and capital markets events that shape its development path. Bookmark this page to review new trial readouts, platform data, and transaction announcements as they are released.
TransCode Therapeutics (RNAZ) announced significant business progress and Q2 2021 financial results, underscoring the impact of its IPO, which generated $28.8 million. The company aims to advance its RNA delivery platform, targeting metastatic tumors with its lead candidate, TTX-MC138, expected to enter clinical trials in 2022. Recent highlights include a $2.3 million NIH grant for TTX-MC138 and key staff appointments. As of June 30, 2021, cash totaled approximately $80K, with expectations to fund operations through 2022, although operational losses are anticipated to increase substantially.
TransCode Therapeutics (Nasdaq: RNAZ) has secured a $2.3 million Fast-Track SBIR grant from the NIH to advance the clinical evaluation of TTX-MC138, aimed at treating metastatic solid tumors. This grant will help fund a first-in-human study targeting metastatic breast cancer, with an eIND application planned for Q1 next year. TTX-MC138 targets MicroRNA-10b, linked to metastatic disease and demonstrated preclinical success in reducing metastatic cancer in murine models. TransCode seeks to leverage its TTX platform for broader therapeutic applications in oncology.
TransCode Therapeutics (Nasdaq: RNAZ) has successfully closed its initial public offering of 7,187,500 shares at $4.00 each, raising gross proceeds of $28.75 million. The offering included the full exercise of the underwriters' over-allotment option. Proceeds are earmarked for testing related to an Investigational New Drug application for TTX-MC138, its lead cancer therapeutic candidate, and for strategic expansion of its drug portfolio. The offering began trading on July 9, 2021, under the symbol RNAZ.
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has priced its initial public offering (IPO) of 6,250,000 shares at $4.00 per share, aiming for gross proceeds of $25 million. The underwriters have a 45-day option to buy an additional 937,500 shares. Proceeds will fund the Phase 0 trial of lead candidate TTX-MC138, development of its drug portfolio, and general corporate purposes. Trading is set to begin on July 9, 2021, with closing expected on July 13, 2021. ThinkEquity manages the offering.